NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") NTLA...
Edity Competitors or Alternatives
Edity's top competitors include ElevateBio, Editas Medicine and Precision BioSciences.
Edity VS ElevateBio
ElevateBio is seen as one of Edity's top competitors. ElevateBio's headquarters is in Waltham, Massachusetts, and was founded in 2017. Like Edity, ElevateBio also works within the Pharmaceuticals & Biotechnology industry. ElevateBio generates 36,416% of Edity's revenue.
Edity VS Editas Medicine
Editas Medicine is one of Edity's top rivals. Editas Medicine was founded in 2013, and its headquarters is in Cambridge, Massachusetts. Like Edity, Editas Medicine also works within the Pharmaceuticals & Biotechnology field. Editas Medicine has 215 more employees than Edity.
Edity VS Precision BioSciences
Precision BioSciences is Edity's #3 rival. Precision BioSciences is a Public company that was founded in 2006 in Durham, North Carolina. Like Edity, Precision BioSciences also competes in the Pharmaceuticals & Biotechnology sector. Compared to Edity, Precision BioSciences has 185 more employees.
Looking for similar companies to Edity?
Similar Companies
Companies in Rehovot with employees in 1-25 range
See 21 companies
Pharmaceuticals & Biotechnology companies in RehovotSee 25 companies
Companies in Rehovot with revenue in $100K-5.0M rangeSee 21 companies
Pharmaceuticals & Biotech Technology companies in AsiaSee 39 companies
Pharmaceuticals & Biotechnology companies in Center DistrictSee 50 companies
Pharmaceuticals & Biotech Technology companies in EMEASee 102 companies
Pharmaceuticals & Biotech Technology companies with employees in 1-25 rangeSee 111 companies
Companies in Center District with employees in 1-25 rangeSee 117 companies
Pharmaceuticals & Biotech Technology companies with revenue in $100K-5.0M rangeSee 152 companies
Trending News for Edity and Edity's Competitors
DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS...
- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and li...
Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial. The post Vertex halts development of...
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA) of a class action....
NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) --WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therap...
Studies on NTLA's gene-edited therapy, nex-z, are progressing well while other pipelines are picking up pace. Stiff competition in the target market is...
BOSTON, MA, Arbor Biotechnologies announced the closing of a $73.9 million Series C financing....
Vertex Pharmaceuticals announced Friday afternoon that it won't move forward with its type 1 diabetes cell therapy that's delivered in a device meant t...
Frequently Asked Questions about Edity
Who are Edity's top competitors?
Edity's top 3 competitors are ElevateBio, Editas Medicine, Precision BioSciences.Who is similar to Edity?
ElevateBio is the most similar to Edity. Editas Medicine and Precision BioSciences are also similar to Edity.
Are Edity and ElevateBio competitors?
Yes, ElevateBio is one of Edity’s top competitors.